{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:11:05Z","timestamp":1773202265778,"version":"3.50.1"},"reference-count":210,"publisher":"Elsevier","isbn-type":[{"value":"9780123737373","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007]]},"DOI":"10.1016\/s0074-7742(06)78003-5","type":"book-chapter","created":{"date-parts":[[2007,3,9]],"date-time":"2007-03-09T12:04:04Z","timestamp":1173441844000},"page":"69-108","source":"Crossref","is-referenced-by-count":451,"title":["Glutamate and Schizophrenia: Phencyclidine, N\u2010Methyl\u2010d\u2010Aspartate Receptors, and Dopamine\u2013Glutamate Interactions"],"prefix":"10.1016","author":[{"given":"Daniel C.","family":"Javitt","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0074-7742(06)78003-5_bib0001","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-005-0092-6","article-title":"Cortical glutamate\u2010dopamine interaction and ketamine\u2010induced psychotic symptoms in man","volume":"182","author":"Aalto","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/0269881106067097","article-title":"Sub\u2010chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin\u2010immunoreactive expression in the rat","author":"Abdul\u2010Monim","year":"2006","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0003","first-page":"166","article-title":"Probing cortical dopamine function in schizophrenia: What can D1 receptors tell us?","volume":"2","author":"Abi\u2010Dargham","year":"2003","journal-title":"World Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0004","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi\u2010Dargham","year":"2002","journal-title":"J. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/S0074-7742(06)78003-5_bib0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2007-979354","article-title":"The NMDA antagonist model for schizophrenia: Promise and pitfalls","volume":"31","author":"Abi\u2010Saab","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0006","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1176\/ajp.156.10.1646","article-title":"Comparison of ketamine\u2010induced thought disorder in healthy volunteers and thought disorder in schizophrenia","volume":"156","author":"Adler","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0007","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N\u2010methyl\u2010D\u2010aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0008","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.bjp.0704381","article-title":"N[3\u2010(4\u2032\u2010fluorophenyl)\u20103\u2010(4\u2032\u2010phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport","volume":"134","author":"Aubrey","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0893-133X(01)00230-5","article-title":"Continuous phencyclidine treatment induces schizophrenia\u2010like hyperreactivity of striatal dopamine release","volume":"25","author":"Balla","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.npp.1300019","article-title":"Subchronic continuous phencyclidine administration potentiates amphetamine\u2010induced frontal cortex dopamine release","volume":"28","author":"Balla","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2004.12.019","article-title":"Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers","volume":"77","author":"Barch","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0012","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2005.10.015","article-title":"Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics","volume":"527","author":"Bennett","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0013","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1523\/JNEUROSCI.22-22-09679.2002","article-title":"Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes","volume":"22","author":"Benquet","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0014","doi-asserted-by":"crossref","first-page":"15730","DOI":"10.1073\/pnas.95.26.15730","article-title":"Modulation of N\u2010methyl\u2010D\u2010aspartate receptor function by glycine transport","volume":"95","author":"Bergeron","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0015","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0920-9964(91)90071-X","article-title":"Neuropsychological deficits in the early course of first episode schizophrenia","volume":"5","author":"Bilder","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ajp.157.4.549","article-title":"Neuropsychology of first\u2010episode schizophrenia: Initial characterization and clinical correlates","volume":"157","author":"Bilder","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0017","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7","article-title":"Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach","volume":"29","author":"Breier","year":"1998","journal-title":"Synapse"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0018","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1111\/j.1460-9568.2003.03073.x","article-title":"Disruption of prepulse inhibition in mice lacking mgluR1","volume":"18","author":"Brody","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0019","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00213-003-1635-3","article-title":"Effect of antipsychotic treatment on the prepulse inhibition deficit of mgluR5 knockout mice","volume":"172","author":"Brody","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0020","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0960-894X(01)00355-9","article-title":"Discovery and SAR of org 24598\u2010a selective glycine uptake inhibitor","volume":"11","author":"Brown","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0021","series-title":"Is Glutamatergic Therapy Efficacious in Schizophrenia? Results from the CONSIST Study.","author":"Buchanan","year":"2004"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0022","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archpsyc.62.5.495","article-title":"Early\u2010stage visual processing and cortical amplification deficits in schizophrenia","volume":"62","author":"Butler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","article-title":"The current status of the dopamine hypothesis of schizophrenia","volume":"1","author":"Carlsson","year":"1988","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/S0074-7742(06)78003-5_bib0024","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1055\/s-2006-931483","article-title":"The neurochemical circuitry of schizophrenia","volume":"39","author":"Carlsson","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and non\u2010deficit forms of schizophrenia: The concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s002130050072","article-title":"Attenuation of specific PCP\u2010evoked behaviors by the potent mglu2\/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine","volume":"148","author":"Cartmell","year":"2000","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000017294","article-title":"Dopamine and N\u2010methyl\u2010D\u2010aspartate receptor interactions in the neostriatum","volume":"20","author":"Cepeda","year":"1998","journal-title":"Dev. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0028","doi-asserted-by":"crossref","first-page":"pe20","DOI":"10.1126\/stke.3332006pe20","article-title":"Where do you think you are going? The NMDA\u2010D1 receptor trap","volume":"2006","author":"Cepeda","year":"2006","journal-title":"Sci. STKE"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0029","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1152\/jn.2001.85.2.659","article-title":"Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor\u2010deficient mice","volume":"85","author":"Cepeda","year":"2001","journal-title":"J. Neurophysiol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0030","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.npp.1300678","article-title":"Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists","volume":"30","author":"Chartoff","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0031","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nature715","article-title":"Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits","volume":"415","author":"Chatterton","year":"2002","journal-title":"Nature"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0032","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1152\/jn.00680.2002","article-title":"Glycine tranporter\u20101 blockade potentiates NMDA\u2010mediated responses in rat prefrontal cortical neurons in vitro and in vivo","volume":"89","author":"Chen","year":"2003","journal-title":"J. Neurophysiol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0033","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000071211","article-title":"Association analysis of the genetic variants of the N\u2010methyl\u2010D\u2010aspartate receptor subunit 2b (NR2b) and treatment\u2010refractory schizophrenia in the Chinese","volume":"47","author":"Chiu","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0034","first-page":"1112","article-title":"Glutamate receptor ligands as anxiolytics","volume":"2","author":"Chojnacka\u2010Wojcik","year":"2001","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0035","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1073\/pnas.182412499","article-title":"Genetic and physiological data implicating the new human gene G72 and the gene for D\u2010amino acid oxidase in schizophrenia","volume":"99","author":"Chumakov","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0036","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0091-3057(02)00848-1","article-title":"Effects of the mglu2\/3 receptor agonist LY379268 on motor activity in phencyclidine\u2010sensitized rats","volume":"73","author":"Clark","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0037","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/jm025570j","article-title":"3\u2010[(2\u2010Methyl\u20101, 3\u2010thiazol\u20104\u2010yl)ethynyl]\u2010pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity","volume":"46","author":"Cosford","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0038","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10673229609017192","article-title":"The glutamatergic dysfunction hypothesis for schizophrenia","volume":"3","author":"Coyle","year":"1996","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0039","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: A review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0040","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/sj.npp.1300772","article-title":"Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter\u20101 SSR504734, a potential new type of antipsychotic","volume":"30","author":"Depoortere","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/S0074-7742(06)78003-5_bib0041","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.schres.2006.06.008","article-title":"COMT genotype and manic symptoms in schizophrenia","volume":"87","author":"DeRosse","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0042","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ajmg.b.30028","article-title":"Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: A case\u2010control study","volume":"128B","author":"Di Maria","year":"2004","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0043","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2006.03.003","article-title":"A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis","volume":"85","author":"Dickinson","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0044","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","article-title":"Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo","volume":"12","author":"Do","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/026988110101500409","article-title":"Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment\u2010resistant schizophrenia: A naturalistic case\u2010series outcome study","volume":"15","author":"Dursun","year":"2001","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0046","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archpsyc.56.10.950","article-title":"Clozapine plus lamotrigine in treatment\u2010resistant schizophrenia","volume":"56","author":"Dursun","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0047","article-title":"Impact of catechol\u2010O\u2010methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders","author":"Ehlis","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0048","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0304-3940(01)02242-X","article-title":"Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia","volume":"313","author":"Erhardt","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0049","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/BF01291892","article-title":"Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics","volume":"104","author":"Evins","year":"1997","journal-title":"J. Neural. Transm."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0050","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo\u2010controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0051","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/sj.npp.1300129","article-title":"Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine","volume":"28","author":"Flores","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0052","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neulet.2004.09.064","article-title":"Enhancement of the NMDA receptor function by reduction of glycine transporter\u20101 expression","volume":"373","author":"Gabernet","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0053","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.npp.1300304","article-title":"Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia","volume":"29","author":"Ghose","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0054","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","article-title":"D\u2010cycloserine added to clozapine for patients with schizophrenia","volume":"153","author":"Goff","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0055","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo\u2010controlled crossover trial of D\u2010cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0056","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A placebo\u2010controlled trial of D\u2010cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0057","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00004714-200110000-00005","article-title":"A placebo\u2010controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia","volume":"21","author":"Goff","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0058","first-page":"S127","article-title":"Placebo\u2010controlled, add\u2010on trial of CX516 (Ampakine) in schizophrenia","volume":"30","author":"Goff","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0059","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1176\/ajp.156.9.1342","article-title":"Longitudinal study of cognitive function in first\u2010episode and recent\u2010onset schizophrenia","volume":"156","author":"Gold","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0060","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/sj.npp.1301049","article-title":"The G72\/G30 gene complex and cognitive abnormalities in schizophrenia","volume":"31","author":"Goldberg","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0061","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","article-title":"Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction","volume":"174","author":"Goldman\u2010Rakic","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0062","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm1418","article-title":"Altered neuregulin 1\u2010erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia","volume":"12","author":"Hahn","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0063","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1523\/JNEUROSCI.18-07-02748.1998","article-title":"Facilitative effects of the ampakine CX516 on short\u2010term memory in rats: Correlations with hippocampal neuronal activity","volume":"18","author":"Hampson","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0064","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1523\/JNEUROSCI.18-07-02740.1998","article-title":"Facilitative effects of the ampakine CX516 on short\u2010term memory in rats: Enhancement of delayed\u2010nonmatch\u2010to\u2010sample performance","volume":"18","author":"Hampson","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0066","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1023\/A:1012328300037","article-title":"The role of glycineB binding site and glycine transporter (GlyT1) in the regulation of [3H]GABA and [3H]glycine release in the rat brain","volume":"26","author":"Harsing","year":"2001","journal-title":"Neurochem. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0067","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0091-3057(02)01078-X","article-title":"The glycine transporter\u20101 inhibitors NFPS and Org 24461: A pharmacological study","volume":"74","author":"Harsing","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0068","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0009-9236(95)90194-9","article-title":"Central nervous system effects of subdissociative doses of (S)\u2010ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers","volume":"58","author":"Hartvig","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0069","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of D\u2010serine in patients with schizophrenia: Evidence in support of the N\u2010methyl\u2010D\u2010aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"Hashimoto","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.pnpbp.2005.04.023","article-title":"Reduced D\u2010serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients","volume":"29","author":"Hashimoto","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0071","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1523\/JNEUROSCI.22-13-05452.2002","article-title":"Metabotropic glutamate receptor 1\u2010induced upregulation of NMDA receptor current: Mediation through the Pyk2\/Src\u2010family kinase pathway in cortical neurons","volume":"22","author":"Heidinger","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0072","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0028-3908(02)00332-5","article-title":"The mgluR5 antagonist MPEP, but not the mgluR2\/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity","volume":"43","author":"Henry","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0073","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S1461145798001242","article-title":"Double\u2010blind, placebo\u2010controlled, crossover trial of D\u2010cycloserine adjuvant therapy for treatment\u2010resistant schizophrenia","volume":"1","author":"Heresco\u2010Levy","year":"1998","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0074","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high\u2010dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco\u2010Levy","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1176\/appi.ajp.159.3.480","article-title":"Placebo\u2010controlled trial of D\u2010cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia","volume":"159","author":"Heresco\u2010Levy","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0076","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-3223(03)00707-8","article-title":"High\u2010dose glycine added to olanzapine and risperidone for the treatment of schizophrenia","volume":"55","author":"Heresco\u2010Levy","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0077","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D\u2010serine efficacy as add\u2010on pharmacotherapy to risperidone and olanzapine for treatment\u2010refractory schizophrenia","volume":"57","author":"Heresco\u2010Levy","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0078","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/sj.npp.1300272","article-title":"Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory","volume":"28","author":"Honey","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0079","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0304-3940(89)90379-0","article-title":"D\u2010cycloserine: A ligand for the N\u2010methyl\u2010D\u2010aspartate coupled glycine receptor has partial agonist characteristics","volume":"98","author":"Hood","year":"1989","journal-title":"Neurosci. Lett."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0080","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/exnr.1997.6581","article-title":"Enhancement by an ampakine of memory encoding in humans","volume":"146","author":"Ingvar","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0081","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1139\/y99-075","article-title":"Silent glutamatergic synapses in the mammalian brain","volume":"77","author":"Isaac","year":"1999","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0082","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00008571-200305000-00006","article-title":"A microsatellite repeat in the promoter of the N\u2010methyl\u2010D\u2010aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia","volume":"13","author":"Itokawa","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0083","first-page":"12","article-title":"Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia","volume":"9","author":"Javitt","year":"1987","journal-title":"Hillside J. Clin. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s002130050168","article-title":"Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse","volume":"129","author":"Javitt","year":"1997","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0084","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0086","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0893-133X(97)00047-X","article-title":"Reversal of phencyclidine\u2010induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide","volume":"17","author":"Javitt","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0087","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0006-3223(98)00237-6","article-title":"A.E. Bennett Research Award. Reversal of phencyclidine\u2010induced effects by glycine and glycine transport inhibitors","volume":"45","author":"Javitt","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0088","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0361-9230(00)00258-6","article-title":"Inhibition of striatal dopamine release by glycine and glycyldodecylamide","volume":"52","author":"Javitt","year":"2000","journal-title":"Brain Res. Bull."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0089","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1017\/S1461145701002590","article-title":"Adjunctive high\u2010dose glycine in the treatment of schizophrenia","volume":"4","author":"Javitt","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.npp.1300313","article-title":"Reversal of phencyclidine\u2010induced dopaminergic dysregulation by N\u2010methyl\u2010D\u2010aspartate receptor\/glycine\u2010site agonists","volume":"29","author":"Javitt","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0091","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.mp.4001552","article-title":"Inhibition of system A\u2010mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action","volume":"10","author":"Javitt","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0092","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.npp.1300589","article-title":"Modulation of striatal dopamine release by glycine transport inhibitors","volume":"30","author":"Javitt","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0093","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0094","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1126\/science.277.5328.953","article-title":"Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long\u2010term administration of phencyclidine","volume":"277","author":"Jentsch","year":"1997","journal-title":"Science"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0095","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1054-3589(08)60870-4","article-title":"Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate: Implications for schizophrenia","volume":"42","author":"Jentsch","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0096","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0022-3565(24)38148-0","article-title":"Synergistic interactions between ampakines and antipsychotic drugs","volume":"289","author":"Johnson","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0097","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1124\/jpet.105.083873","article-title":"Prolonged positive modulation of alpha\u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolepropionic acid (AMPA) receptors induces calpain\u2010mediated PSD\u201095\/Dlg\/ZO\u20101 protein degradation and AMPA receptor down\u2010regulation in cultured hippocampal slices","volume":"314","author":"Jourdi","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0098","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0099","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/appi.ajp.159.5.761","article-title":"PET study of D(1) dopamine receptor binding in neuroleptic\u2010naive patients with schizophrenia","volume":"159","author":"Karlsson","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0101","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0102","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0006-3223(00)00976-8","article-title":"Modulation of amphetamine\u2010induced striatal dopamine release by ketamine in humans: Implications for schizophrenia","volume":"48","author":"Kegeles","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/syn.10010","article-title":"NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans","volume":"43","author":"Kegeles","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0104","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.103.048702","article-title":"Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents","volume":"306","author":"Kinney","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0105","doi-asserted-by":"crossref","first-page":"7586","DOI":"10.1523\/JNEUROSCI.23-20-07586.2003","article-title":"The glycine transporter type 1 inhibitor N\u2010[3\u2010(4\u2032\u2010fluorophenyl)\u20103\u2010(4\u2032\u2010phenylphenoxy)propyl]sarcosine potentiates NMDA receptor\u2010mediated responses in vivo and produces an antipsychotic profile in rodent behavior","volume":"23","author":"Kinney","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0106","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1523\/JNEUROSCI.4722-05.2006","article-title":"A specific role for NR2A\u2010containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons","volume":"26","author":"Kinney","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0107","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.biopsych.2004.04.006","article-title":"Is the G72\/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis","volume":"56","author":"Korostishevsky","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0108","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0301-0082(94)90037-X","article-title":"Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum","volume":"44","author":"Kotter","year":"1994","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0109","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopsych.2004.06.029","article-title":"Placebo\u2010controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia","volume":"56","author":"Kremer","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/S0074-7742(06)78003-5_bib0111","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0112","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0306-4522(00)00480-2","article-title":"Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum","volume":"102","author":"Kulagina","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0114","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1176\/ajp.155.6.835","article-title":"Association between catechol O\u2010methyltransferase genotype and violence in schizophrenia and schizoaffective disorder","volume":"155","author":"Lachman","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/S0074-7742(06)78003-5_bib0116","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","article-title":"Glycine transporter I inhibitor, N\u2010methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia","volume":"60","author":"Lane","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0117","first-page":"211","article-title":"Imaging dopamine transmission in schizophrenia. A review and meta\u2010analysis","volume":"42","author":"Laruelle","year":"1998","journal-title":"Q. J. Nucl. Med."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0118","first-page":"1182","article-title":"SPECT imaging of striatal dopamine release after amphetamine challenge","volume":"36","author":"Laruelle","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0119","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine\u2010induced dopamine release in drug\u2010free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: Relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0121","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S0006-3223(03)00374-3","article-title":"Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal\u2010lesioned rats: Reversal by glycine and a glycine transporter inhibitor","volume":"54","author":"Le Pen","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0122","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1523\/JNEUROSCI.20-11-04011.2000","article-title":"Intracellular modulation of NMDA receptor function by antipsychotic drugs","volume":"20","author":"Leveque","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0123","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1176\/appi.ajp.159.10.1790","article-title":"Elevated homocysteine levels in young male patients with schizophrenia","volume":"159","author":"Levine","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0124","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0125","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1097\/00001756-199909090-00017","article-title":"Behavioral effects of chronic phencyclidine in monkeys","volume":"10","author":"Linn","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0126","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-005-2210-x","article-title":"Modulators of the glycine site on NMDA receptors, D\u2010serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia","volume":"179","author":"Lipina","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1\u20133","key":"10.1016\/S0074-7742(06)78003-5_bib0127","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2006.06.020","article-title":"No association of G72 and D\u2010amino acid oxidase genes with schizophrenia","volume":"87","author":"Liu","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0128","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0306-4522(02)00652-8","article-title":"Effects of ketamine and N\u2010methyl\u2010D\u2010aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268","volume":"117","author":"Lorrain","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1176\/ajp.119.1.61","article-title":"Model psychoses and schizophrenia","volume":"119","author":"Luby","year":"1962","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1176\/appi.ajp.162.3.475","article-title":"Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never\u2010medicated patients with first\u2010episode psychosis","volume":"162","author":"MacDonald","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0131","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0304-3940(02)01261-2","article-title":"Different roles of group I and group II metabotropic glutamate receptors on phencyclidine\u2010induced dopamine release in the rat prefrontal cortex","volume":"336","author":"Maeda","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0132","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ajmg.b.10041","article-title":"Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: Linkage disequilibrium mapping using SNPs evenly distributed across the gene region","volume":"116B","author":"Makino","year":"2003","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0133","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0893-133X(95)00137-3","article-title":"NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers","volume":"14","author":"Malhotra","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0134","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0006-3223(96)00546-X","article-title":"Clozapine blunts N\u2010methyl\u2010D\u2010aspartate antagonist\u2010induced psychosis: A study with ketamine","volume":"42","author":"Malhotra","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine\u2010induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic\u2010free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0136","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(01)00311-5","article-title":"Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series","volume":"57","author":"Marenco","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0137","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1113\/jphysiol.2004.063321","article-title":"Glycine transporter type 1 blockade changes NMDA receptor\u2010mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels","volume":"557","author":"Martina","year":"2004","journal-title":"J. Physiol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0138","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1113\/jphysiol.2004.080655","article-title":"Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice","volume":"563","author":"Martina","year":"2005","journal-title":"J. Physiol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0139","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.2044-8341.1961.tb00936.x","article-title":"Disorders of attention and perception in early schizophrenia","volume":"34","author":"McGhie","year":"1961","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.mp.4001193","article-title":"Clozapine\u2010induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1","volume":"8","author":"Melone","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0141","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.mp.4001860","article-title":"Impact of complex genetic variation in COMT on human brain function","volume":"11","author":"Meyer\u2010Lindenberg","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0142","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0361-9230(95)02144-2","article-title":"Effects of MK\u2010801 on spontaneous and amphetamine\u2010stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats","volume":"40","author":"Miller","year":"1996","journal-title":"Brain Res. Bull."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0143","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2174\/156802606777057562","article-title":"The NMDA\/D1 receptor complex as a new target in drug development","volume":"6","author":"Missale","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0144","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1254\/jphs.CPJ06007X","article-title":"Molecular mechanism of neuronal plasticity: Induction and maintenance of long\u2010term potentiation in the hippocampus","volume":"100","author":"Miyamoto","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0896-6273(03)00757-8","article-title":"Bringing order to the glutamate chaos in schizophrenia","volume":"40","author":"Moghaddam","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0146","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0147","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.npp.1300342","article-title":"Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers","volume":"29","author":"Morgan","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0148","first-page":"298","article-title":"Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: A dose\u2010response study","volume":"172","author":"Morgan","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0149","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cne.10937","article-title":"Distribution of mgluR1alpha and mgluR5 immunolabeling in primate prefrontal cortex","volume":"467","author":"Muly","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0150","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1176\/appi.ajp.162.12.2352","article-title":"Altered prefrontal dopaminergic function in chronic recreational ketamine users","volume":"162","author":"Narendran","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0151","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","article-title":"Ketamine\u2010induced NMDA receptor hypofunction as a model of memory impairment and psychosis","volume":"20","author":"Newcomer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0152","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.neuro.23.1.185","article-title":"Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens","volume":"23","author":"Nicola","year":"2000","journal-title":"Annu. Rev. Neurosci.,"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0153","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","article-title":"Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET","volume":"385","author":"Okubo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0154","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0155","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S1471-1931(00)00020-3","article-title":"Dopamine\u2010mediated regulation of striatal neuronal and network interactions","volume":"23","author":"Onn","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0156","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1961","journal-title":"Psychol. Rep."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0157","first-page":"1209","article-title":"Effects of ketamine on sensory perception: Evidence for a role of N\u2010methyl\u2010D\u2010aspartate receptors","volume":"260","author":"Oye","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0158","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1523\/JNEUROSCI.23-20-07659.2003","article-title":"Group I metabotropic glutamate receptors in the monkey striatum: Subsynaptic association with glutamatergic and dopaminergic afferents","volume":"23","author":"Paquet","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0159","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-005-0177-2","article-title":"The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers","volume":"183","author":"Parwani","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0160","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/syn.890020413","article-title":"Biphasic modulation of evoked [3H]D\u2010aspartate release by D\u20102 dopamine receptors in rat striatal slices","volume":"2","author":"Peris","year":"1988","journal-title":"Synapse"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0161","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00210-002-0619-x","article-title":"Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto\u2010parietal cortex in rats: Microdialysis and electrophysiological studies","volume":"366","author":"Pietraszek","year":"2002","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0162","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0028-3908(02)00082-5","article-title":"Multiple MPEP administrations evoke anxiolytic\u2010 and antidepressant\u2010like effects in rats","volume":"43","author":"Pilc","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0163","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/1568007023339328","article-title":"The metabotropic glutamate receptors: Structure, activation mechanism and pharmacology","volume":"1","author":"Pin","year":"2002","journal-title":"Curr. Drug Target CNS Neurol. Disord."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0164","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archpsyc.57.12.1149","article-title":"Auditory sensory dysfunction in schizophrenia: Imprecision or distractibility?","volume":"57","author":"Rabinowicz","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0165","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0893-133X(98)00030-X","article-title":"Does ketamine\u2010mediated N\u2010methyl\u2010D\u2010aspartate receptor antagonism cause schizophrenia\u2010like oculomotor abnormalities?","volume":"19","author":"Radant","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0166","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF03033297","article-title":"Calcium binding protein markers of GABA deficits in schizophrenia: Postmortem studies and animal models","volume":"6","author":"Reynolds","year":"2004","journal-title":"Neurotox. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0167","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2004.02.003","article-title":"Chronic phencyclidine administration induces schizophrenia\u2010like changes in N\u2010acetylaspartate and N\u2010acetylaspartylglutamate in rat brain","volume":"73","author":"Reynolds","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0168","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00041444-199722000-00002","article-title":"A linkage study of the N\u2010methyl\u2010D\u2010aspartate receptor subunit gene loci and schizophrenia in southern African Bantu\u2010speaking families","volume":"7","author":"Riley","year":"1997","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0169","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.npp.1300642","article-title":"Selective cognitive impairments associated with NMDA receptor blockade in humans","volume":"30","author":"Rowland","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0170","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/archpsyc.1991.01810310036007","article-title":"Neuropsychological function in schizophrenia: Selective impairment in memory and learning","volume":"48","author":"Saykin","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0171","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1568007024606177","article-title":"Preclinical pharmacology of mglu2\/3 receptor agonists: Novel agents for schizophrenia?","volume":"1","author":"Schoepp","year":"2002","journal-title":"Curr. Drug Target CNS Neurol. Disord."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0172","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.mp.4001421","article-title":"Examination of G72 and D\u2010amino\u2010acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder","volume":"9","author":"Schumacher","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0173","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","article-title":"Increased cortical kynurenate content in schizophrenia","volume":"50","author":"Schwarcz","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0174","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2004.03.020","article-title":"Schizophrenia patients demonstrate a distinctive pattern of decision\u2010making impairment on the Iowa Gambling Task","volume":"72","author":"Shurman","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0175","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ajmg.b.30275","article-title":"The involvement of ErbB4 with schizophrenia: Association and expression studies","volume":"141","author":"Silberberg","year":"2006","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0176","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0166-2236(90)90106-K","article-title":"The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones","volume":"13","author":"Smith","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0177","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0893-133X(97)00092-4","article-title":"Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C\u2010raclopride in normal human subjects","volume":"18","author":"Smith","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0178","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/syn.890190405","article-title":"Glutamate\/dopamine D1\/D2 balance in the basal ganglia and its relevance to Parkinson's disease","volume":"19","author":"Starr","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0180","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/342734","article-title":"Neuregulin 1 and susceptibility to schizophrenia","volume":"71","author":"Stefansson","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0181","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuroscience.2005.10.014","article-title":"Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia","volume":"137","author":"Steullet","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0182","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1176\/ajp.152.10.1517","article-title":"Auditory sensory (\u201cechoic\u201d) memory dysfunction in schizophrenia","volume":"152","author":"Strous","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145703003900","article-title":"Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: Relation to negative symptoms","volume":"7","author":"Sumiyoshi","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0184","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0006-3223(97)00427-7","article-title":"Schizophrenia and impaired homocysteine metabolism: A possible association","volume":"44","author":"Susser","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0185","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/jpet.102.038422","article-title":"The group II metabotropic glutamate receptor agonist (\u2013)\u20102\u2010oxa\u20104\u2010aminobicyclo[3.1.0.]hexane\u20104,6\u2010dicarboxylate (LY379268) and clozapine reverse phencyclidine\u2010induced behaviors in monoamine\u2010depleted rats","volume":"303","author":"Swanson","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0186","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1046\/j.1471-4159.2000.0751775.x","article-title":"Target\u2010specific glutamatergic regulation of dopamine neurons in the ventral tegmental area","volume":"75","author":"Takahata","year":"2000","journal-title":"J. Neurochem."},{"issue":"Suppl. 3","key":"10.1016\/S0074-7742(06)78003-5_bib0187","first-page":"29","article-title":"Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions","volume":"10","author":"Tamminga","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0188","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0006-8993(00)02951-6","article-title":"The AMPAR subunit GluR2: Still front and center\u2010stage","volume":"886","author":"Tanaka","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0189","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0006-3223(03)00524-9","article-title":"Lamotrigine in treatment\u2010resistant schizophrenia: A randomized placebo\u2010controlled crossover trial","volume":"54","author":"Tiihonen","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0190","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.biopsych.2004.10.019","article-title":"Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains","volume":"57","author":"Torrey","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0191","first-page":"1","article-title":"Effect of glycine derivatives on behavioral changes induced by 3\u2010mercaptopropionic acid or phencyclidine in mice","volume":"11","author":"Toth","year":"1986","journal-title":"Res. Comm. Psychol. Psychiat. Behav."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0192","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archpsyc.1995.03950220039008","article-title":"Abnormal excitatory neurotransmitter metabolism in schizophrenic brains","volume":"52","author":"Tsai","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0194","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"D\u2010serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0193","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"D\u2010serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0195","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N\u2010methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0196","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.0402662101","article-title":"Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype","volume":"101","author":"Tsai","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/S0074-7742(06)78003-5_bib0197","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.biopsych.2005.06.032","article-title":"D\u2010alanine added to antipsychotics for the treatment of schizophrenia","volume":"59","author":"Tsai","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0198","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1523\/JNEUROSCI.1021-04.2004","article-title":"Dopamine\u2010glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms","volume":"24","author":"Tseng","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0199","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/sj.npp.1300732","article-title":"Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys","volume":"30","author":"Tsukada","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2004.05.005","article-title":"Glutamatergic drugs for schizophrenia: A systematic review and meta\u2010analysis","volume":"72","author":"Tuominen","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0201","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archpsyc.57.12.1139","article-title":"Ketamine\u2010induced deficits in auditory and visual context\u2010dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia","volume":"57","author":"Umbricht","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0202","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0893-133X(99)00014-7","article-title":"D\u2010cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double\u2010blind, parallel, placebo\u2010controlled study","volume":"21","author":"van Berckel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0203","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.npp.1300902","article-title":"Modulation of amphetamine\u2010induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non\u2010human primates studied with positron emission tomography","volume":"31","author":"van Berckel","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3956(99)00031-X","article-title":"Effects of (S)\u2010ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans","volume":"34","author":"Vollenweider","year":"2000","journal-title":"J. Psychiatr. Res."},{"issue":"Suppl. A","key":"10.1016\/S0074-7742(06)78003-5_bib0205","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.clinthera.2005.07.016","article-title":"Genetic mechanisms of psychosis: In vivo and postmortem genomics","volume":"27","author":"Weinberger","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0206","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-3223(01)01252-5","article-title":"Prefrontal neurons and the genetics of schizophrenia","volume":"50","author":"Weinberger","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0207","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1523\/JNEUROSCI.22-01-00294.2002","article-title":"Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: Studies combining in vivo intracellular recordings and reverse microdialysis","volume":"22","author":"West","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0208","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archpsyc.55.12.1093","article-title":"Word and tone working memory deficits in schizophrenia","volume":"55","author":"Wexler","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/S0074-7742(06)78003-5_bib0209","first-page":"79","article-title":"Effects of oral glycine in the schizophrenia prodrome","volume":"70","author":"Woods","year":"2004","journal-title":"Schiz. Res."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0210","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1523\/JNEUROSCI.5120-05.2006","article-title":"Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile","volume":"26","author":"Yee","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/S0074-7742(06)78003-5_bib0211","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pscychresns.2004.11.006","article-title":"Functional magnetic resonance imaging studies of schizophrenic patients during word production: Effects of D\u2010cycloserine","volume":"138","author":"Yurgelun\u2010Todd","year":"2005","journal-title":"Psychiatry Res."}],"container-title":["International Review of Neurobiology","Integrating the Neurobiology of Schizophrenia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T17:43:56Z","timestamp":1736876636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774206780035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"ISBN":["9780123737373"],"references-count":210,"URL":"https:\/\/doi.org\/10.1016\/s0074-7742(06)78003-5","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2007]]}}}